About | How We Got Here

Jan 2010: CYCLIST Phase III trial enrolls last patient - The trial enrolled in just over a year after the initiation of 19 investigational sites. APT believes that positive data will be sufficient to support US and EU marketing applications. For more information on the CYCLIST study, please visit www.cycliststudy.com
Sept 2008: APT raises Series B – APT completes a $32 million round of financing to fund completion of the Phase III trial of CIS.
Oct 2007: Investigator Team Formed and Protocol Initiated – APT recruits most of the leading lung transplant centers in North America to participate in the CYCLIST study.
Oct 2007: APT raises Series A funding – The funding allows APT to hire the management team needed initiate the Phase III trial.
May 2007: APT sublicenses CIS from Novartis – Novartis acquired the rights to the product through their acquisition of the Chiron Corporation.
Jan 2006: Results of the CIS phase II published in New England Journal of Medicine Investigators at the University of Pittsburgh concluded that CIS did not improve the rate of acute rejection, but it did improve survival and extend periods of chronic rejection–free survival (Iacono et al 2006).
July 2005: FDA issues an approvable letter to Chiron Corporation for cyclosporine inhalation solution – The FDA outlines the requirements for a study to support approval of CIS. APT’s CEO, Dr. Stephen Dilly, was the Chief Medical Officer at Chiron at this time. Several APT team members also worked at Chiron and understand the drug well.